Unique ID issued by UMIN | UMIN000033528 |
---|---|
Receipt number | R000038197 |
Scientific Title | An exploratory study of the effects of continuous intake of high gamma PGA natto on physique and glucose and lipid metabolism. |
Date of disclosure of the study information | 2018/07/30 |
Last modified on | 2020/07/27 09:23:57 |
An exploratory study of the effects of continuous intake of high gamma PGA natto on physique and glucose and lipid metabolism.
A pilot study of high gamma PGA natto continuous intake
An exploratory study of the effects of continuous intake of high gamma PGA natto on physique and glucose and lipid metabolism.
A pilot study of high gamma PGA natto continuous intake
Japan |
Healthy subjects
Not applicable | Adult |
Others
NO
To examine the efficacy of the high gamma PGA natto on physique and glucose and lipid metabolism.
Efficacy
Exploratory
Explanatory
Not applicable
Blood lipid level(TG, HDL-C, LDL-C, TC) at 12 weeks.
1.Body weight, Waist circumference
2.Blood pressure
3.Biomarkers(fasting blood gulcose, HbA1c, insulin, C-peptide, AST, ALT, amma GTP, BUN, Cr, UA, FFA, TP, Alb)
4.Amount of test meal consumption
5.Defecation frequency
6.Organoleptic evaluation
Interventional
Cross-over
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Food |
Low gamma PGA natto.
40g per day for 6weeks.
High gamma PGA natto.
40g per day for 6weeks.
40 | years-old | <= |
64 | years-old | >= |
Male and Female
1.BMI not less than 23.0 kg/m2, under 25.0 kg/m2
2. Capable of giving informed consent.
1. Fasting blood glucose not less than 126 mg/dL and/or HbA1c not less than 6.5%
2. TG not less than 200 mg/dL and/or LDL-C not less than 160 mg/dL
3. SBP not less than 160 mmHg and/or DBP not less than 100 mmHg
4. Subjects who are treated for diabetes and/or hyperlipidemia and/or hypertension.
5. Subjects who are habitually taking supplement (including "food for specified health use", and "foods with function claims") that include lactic acid bacterium, bifidobacteria, oligosaccharide, dietary fiber, and ingredients of natto.
6. Subjects who are enrollment in another interventional study
7. Subjects who were recognized unsuitable for this study by the Investigator.
30
1st name | Koichi |
Middle name | |
Last name | Hashimoto |
University of Tsukuba, Faculty of Medicene
Clinical and Translational Research Methodology
305-8575
1-1-1 Tennodai, Tsukuba, Ibaraki, Japan
029-853-3064
koichi.hashimoto@md.tsukuba.ac.jp
1st name | Koichi |
Middle name | |
Last name | Hashimoto |
University of Tsukuba, Faculty of Medicene
Clinical and Translational Research Methodology
305-8575
1-1-1 Tennodai, Tsukuba, Ibaraki, Japan
029-853-3064
koichi.hashimoto@md.tsukuba.ac.jp
Fuculty of Medicine
University of Tsukuba
Ministry of Agriculture, Forestry and Fisheries
Japanese Governmental office
1.Takanofoods Co.,Ltd.
2.Industrial technology innovation center of Ibaraki prefecture.
3.National agriculture and food research organization, food research institute.
Clinical Research Ethics Committee of University of Tsukuba Hospital
1-1-1 Tennodai, Tsukuba, Ibaraki, Japan
029-853-3914
chiken@un.tsukuba.ac.jp
NO
筑波大学附属病院(茨城県)
2018 | Year | 07 | Month | 30 | Day |
Unpublished
No longer recruiting
2018 | Year | 07 | Month | 30 | Day |
2018 | Year | 08 | Month | 18 | Day |
2019 | Year | 01 | Month | 19 | Day |
2018 | Year | 07 | Month | 26 | Day |
2020 | Year | 07 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038197